CTOs on the Move

LTC Group

www.ltcgroup.com

 
LTC Group is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Simonmed Imaging

SimonMed Imaging is one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States. Our practice consists of over 200 highly-experienced subspecialty-trained radiologists, and we operate across 9 states with over 150 accredited facilities that are ACR-RADSITE certified with certified technologists and equipment. We specialize in using the newest diagnostic imaging technologies and bringing them to the community in an affordable and accessible way. Our logo See Tomorrow Today recognizes that new technology can help provide a more accurate diagnosis but needs to be readily available and affordable.

CBOSS

CBOSS is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Youngstown, OH. To find more information about CBOSS, please visit www.cboss.com

SynergenX Health

Reinvigorate your life for Low T, menopause symptoms, weight loss. Low-T & Hormone Treatment in Houston, Dallas, San Antonio, Texas and Chicago, Illinois, by licensed Testosterone and HRT treatment professionals.

Eurogentec North America

Eurogentec North America is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.